



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)
Kenju MIURA et al.) Art Unit: 1646
Application No.: 10/649,952) Examiner: Unassigned
Filed: August 28, 2003)

For: PROMOTERS OF THE GROWTH AND/OR DIFFERENTIATION OF
HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITORS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants respectfully requests consideration of the references listed on the attached Form PTO/SB/08A. Copies of the references listed are also enclosed.

Applicants respectfully point out that the submission of the listed documents in this Information Disclosure Statement is not an admission that it is a prior art or that it is material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made.

Applicants respectfully request that the Examiner consider the references cited on the Form PTO/SB/08A and that the Examiner indicate that the references have been considered in this application by returning a copy of the Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609.

This IDS is submitted prior to the issuance of a first Office Action on the merits; therefore, it is believed that no fees are required in connection therewith. If any fees are necessitated by the filing of this Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

Date: March 10, 2004

By: Robert M. Schulman
Robert M. Schulman
Registration No. 31,196

David H. Milligan
Registration No. 42,893

HUNTON & WILLIAMS LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, D.C. 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

RMS/DHM/cbt



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/649,952
		Filing Date	August 28, 2003
		First Named Inventor	Kenju MIURA
		Group Art Unit	1646
		Examiner Name	Unassigned
Sheet 1 of 3	Attorney Docket Number	58777.000013	

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	5,464,817		STOSSEL et al.	11-07-1995	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1	JP	05050603		Kozo	03-02-1993	Abstract	
	F2	JP	06269284A		Takehisa	09-27-1994	Abstract	
	F3	JP	08510998T2			11-19-1996	Abstract	
	F4	JP	10067662A		Muellner et al.	03-10-1998	Abstract	
	F5	JP	10087484A		Muellner et al.	04-07-1998	Abstract	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P1	International Search Report - PCT/JP02/13862, pp. 1-2	
	P2	GILLET, G.T. et al., "Mapping of human non-muscle type cofilin (CFL1) to chromosome 11q13 and muscle-type cofilin (CFL2) to chromosome 14", Ann. Hum. Genet. (1996), Vol. 60, pp. 201-211	
	P3	GÖTZE, KATHARINA S. et al., "gp130-Stimulating designer cytokine Hyper-interleukin-6 synergizes with murine stroma for long-term survival of primitive human hematopoietic progenitor cells", Experimental Hematology 29 (2001), pp. 822-832	
	P4	HUANG, ERIC et al., "The Hematopoietic Growth Factor KL Is Encoded by the SI Locus and Is the Ligand of the c-kit Receptor, the Gene Product of the W Locus", Cell (October 5, 1990), Vol. 63, pp. 225-233	


Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/649,952
		Filing Date	August 28, 2003
		First Named Inventor	Kenju MIURA
		Group Art Unit	1646
		Examiner Name	Unassigned
		Attorney Docket Number	58777.000013
Sheet	2	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T. ²
	P5	IGAKU, JIKKEN, "Experimental Medicine", Experimental Medicine (March 28, 1994), Vol. 12, No. 3, pp. 45-51	
	P6	IGAKU, JIKKEN, Experimental Medicine (May 13, 1994), Vol. 12, No. 4, pp. 24-28	
	P7	KAWASHIMA, ICHIRO et al., "CD34 ⁺ Human Marrow Cells That Express Low Levels of Kit Protein Are Enriched For Long-Term Marrow-Engrafting Cells", Blood (May 15, 1996), Vol. 87, No. 10, pp. 4136-4142	
	P8	KIMURA, TAKAFUMI et al., "Simultaneous Activation of Signals Through gp130, c-kit, and Interleukin-3 Receptor Promotes a Trilineage Blood Cell Production in the Absence of Terminally Acting Lineage-Specific Factors", Blood (December 15, 1997), Vol. 90, No. 12, pp. 4767-4778	
	P9	LYMAN PhD, STEWART D., "Biological effects and potential clinical applications of Flt3 ligand", Curr. Hematol. (1998), Vol 5, No. 3, pp. 192-196	
	P10	MOON, ANNE et al., "The ADF/Cofilin Proteins: Stimulus-responsive Modulators of Actin Dynamics", Molecular Biology of the Cell (November 1995), Vol. 6, pp. 1423-1431	
	P11	MOORE, MALCOLM A. S., "Clinical Implications of Positive and Negative Hematopoietic Stem Cell Regulators", Blood (July 1, 1991), Vol. 78, No. 1, pp. 1-19, The Journal of The American Society of Hematology	
	P12	MORIYAMA, KENJI et al., "Molecular functions of cofilin which regulates reorganization of actin cytoskeleton", Seikagaku (1999), Vol. 71, No. 2, pp. 101-114, Department of Cell Biology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.	
	P13	NAKAHATA, TATSUTOSHI et al., "Role of glycoprotein 130 and c-Kit signaling in proliferation and differentiation of human hematopoietic progenitor cells", Cancer Chemother Pharmacol (1996), Vol. 38, (Suppl), pp. S64-S68	
	P14	OGAWA, K. et al., Coding sequence of human placenta Cofilin cDNA, Nucleic Acids Research (1990), Vol. 18, No. 23	
	P15	OGAWA, MAKIO, "Differentiation and Proliferation of Hematopoietic Stem Cells", Blood (June 1, 1993), Vol. 81, No. 11, pp. 2844-2853	
	P16	PIACIBELLO, WANDA et al., "Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood," Blood (April 15, 1997), Vol. 89, No. 8, pp. 2644-2653, Rapid Communication	

Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450 Alexandria, VA 22313-1450

+



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/649,952		
		Filing Date	August 28, 2003		
		First Named Inventor	Kenju MIURA		
		Group Art Unit	1646		
		Examiner Name	Unassigned		
Sheet	3	of	3	Attorney Docket Number	58777.000013

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P17	WILLIAMS, DOUGLAS E. et al., "Identification of a Ligand for the c-kit Proto-Oncogene," Cell (October 5, 1990), Vol. 63, pp. 167-174	
	P18	ZSEBO, KRISZTINA M. et al., "Identification, Purification, and Biological Characterization of Hematopoietic Stem Cell Factor from Buffalo Rat Liver-Conditioned Medium", Cell (October 5, 1990), Vol. 63, pp. 195-201	
	P19		
	P20		
	P21		
	P22		
	P23		
	P24		
	P25		
	P26		
	P27		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450 Alexandria, VA 22313-1450